Immuneering Corporation (IMRX)
NASDAQ · Healthcare
Immuneering Corporation Shareholder Equity 2020–2023
Immuneering Corporation annual/quarterly shareholder equity history from 2020 to 2023. Shareholder equity represents the net worth of a company, calculated as total assets minus total liabilities.
- Immuneering Corporation shareholder equity for the quarter ending December 31, 2023 were 90.6M, a 17.55% decrease year-over-year.
- Immuneering Corporation shareholder equity for 2023 were 90.6M, a 17.55% decrease from 2022.
- Immuneering Corporation shareholder equity for 2022 were 109.9M, a 29.57% decrease from 2021.
- Immuneering Corporation shareholder equity for 2021 were 156.0M, a 793.82% decrease from 2020.
- Immuneering Corporation shareholder equity for 2020 were -22.5M.
Shareholder Equity
QUARTERLY · $B
YOY QUARTERLY GROWTH · %
| Immuneering Corporation Annual Shareholder Equity (Millions of US $) | |
|---|---|
| 2023 | $91 |
| 2022 | $110 |
| 2021 | $156 |
| 2020 | $-22 |
| Immuneering Corporation Quarterly Shareholder Equity (Millions of US $) | |
|---|---|
| 2023-12-31 | $91 |
| 2022-12-31 | $110 |
| 2021-12-31 | $156 |
| 2020-12-31 | $-22 |
Immuneering Corporation Shareholder Equity — FAQ
Immuneering Corporation (IMRX) shareholder equity over the last 4 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see IMRX's shareholder equity history?
The chart and table above show Immuneering Corporation's shareholder equity by year and by quarter, including the growth rate.